Amgen wants in on the booming weight loss drug market — and it's taking a different approach

  • 📰 CNBC
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.

Amgen is among a crowded field of drugmakers racing to develop the next blockbuster weight loss drug — but it's taking an entirely different approach than its rivals.

It's also unclear whether Amgen's treatments will be cheaper than the existing weight loss drugs, which cost around $1,000 per month. But while Zepbound activates a second hormone receptor called GIP, Amgen's drug blocks it. Wegovy does not target GIP, which suppresses appetite like GLP-1 but may also improve how the body breaks down sugar and fat.

Patients who received a single shot of the highest dose of MariTide lost up to 8.2% of their body weight after 92 days. That suggests a single injection of the drug has a prolonged weight loss effect, according to the study authors. Amgen's trial used monthly dosing in part because patients saw sustained weight loss whether they had a single injection or multiple shots of the company's drug, according to the study authors.

But he noted that a patient's choice may also depend on whether the level of weight loss and side effects of Amgen's drug end up being on par with those of the existing weekly injections.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 12. in BR

Brasil Últimas Notícias, Brasil Manchetes